Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 14.62
-2.86 %
$ 844 M
Market Cap
12.5
P/E
CASH FLOW STATEMENT
67.7 M
OPERATING CASH FLOW
-26.5 M
INVESTING CASH FLOW
-48.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Embecta Corp.
| Net Income | 70.4 M |
| Depreciation & Amortization | 32.6 M |
| Capital Expenditures | -26.5 M |
| Stock-Based Compensation | 21.5 M |
| Change in Working Capital | -80 M |
| Others | -57.2 M |
| Free Cash Flow | 41.2 M |
Cash Flow
Millions
| Sep-2023 | Sep-2022 | Sep-2021 | Sep-2020 | Sep-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | 70.4 | 223.6 | 415.0 | 427.6 | 432.0 |
| Depreciation & Amortization | 32.6 | 31.7 | 38.0 | 38.3 | 36.0 |
| Deferred Income Tax | 14.3 | (26.5) | (2.0) | (2.2) | (6.0) |
| Stock Based Compensation | 21.5 | 18.7 | 12.8 | 12.7 | 12.0 |
| Other Operating Activities | 8.9 | 72.3 | 24.0 | 9.4 | 9.0 |
| Change in Working Capital | (80.0) | 92.4 | (32.0) | 12.7 | 22.0 |
| Cash From Operations | 67.7 | 412.2 | 456.0 | 498.5 | 505.0 |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (26.5) | (24.0) | (39.0) | (41.9) | (69.0) |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (26.5) | (24.0) | (39.0) | (41.9) | (69.0) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | (3.6) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (10.7) | 1 437.8 | 0 | 0 | 0 |
| Dividends Paid | (34.4) | (8.6) | 0 | 0 | 0 |
| Other Financing Activities | (3.6) | (1 477.2) | (417.1) | (456.6) | (436.0) |
| Cash From Financing Activities | (48.7) | (48.0) | (417.0) | (456.6) | (436.0) |
| CHANGE IN CASH | |||||
| Net Change In Cash | (4.4) | 330.9 | 0 | 0 | 0 |
| FREE CASH FLOW | |||||
| Free Cash Flow | 41.2 | 388.2 | 417.0 | 456.6 | 436.0 |